67 results about "Differentiation Inhibitor" patented technology

A medical device comprising a supporting structure capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may include one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

Amino acids constituting a physiologically active molecule human delta 2; a gene arrangement thereof; and an antibody thereto. The human delta 2 molecule, at least the amino acid sequence described in SEQ ID NO: 1 of the sequence listing, functions as a chemical useful for proliferation of undifferentiated blood cells and inhibition of differentiation, and hence can be utilized as pharmaceuticals and medical supplies.

The object of the present invention is to provide a differentiation inhibiting agent which allows culture of a stem cell or an embryonic stem cell in an undifferentiated state without use of any feeder cell, a method for culturing using the same, a cell culture liquid using the same, and a cell prepared by culturing using this differentiation inhibiting agent. The present invention provides a differentiation inhibiting agent which comprises a low molecular weight compound, especially a tetrahydroisoquinoline derivative, as an active ingredient; a method for safely culturing a stem cell in large scale in undifferentiated state in the absence of feeder cell which comprises culturing a stem cell by using a tetrahydroisoquinoline derivative; a culture liquid for stem cells comprising a tetrahydroisoquinoline derivative; and a cell which is obtained by culture using a tetrahydroisoquinoline derivative as a differentiation inhibiting agent.

The invention belongs to the technical fields of immunology and tumor therapy, and relates to a preparation method and a use of a TCR gene modified CD8+T memory stem cell. The method comprises the following steps: co-incubating a tumor antigen and an immature dendritic cell to obtain a specific tumor antigen-supported mature dendritic cell, co-culturing the specific tumor antigen-supported maturedendritic cell and a CD8+ naive T cell, and adding a stem cell differentiation inhibitor to promote the generation of a CD8+ stem cell-like memory T lymphocyte; separating the CD8+ stem cell-like memory T lymphocyte; and cloning a T cell receptor gene (TCR) for specifically identifying a specific antigenic epitope, and carrying out lentivirus packaging or retroviral vector cotransfection on an autologous CD8+ Tscm cell to in-vitro prepare a CD8+ TCR-Tscm cell specific for different tumor specific antigens. The CD8+ TCR-Tscm cell prepared by the method has the advantages of overcoming of the tumor heterogeneity, high specificity, few adverse reactions, and highly-efficient and lasting tumor preventing and treating effects.

Non-embryonic blastomere-like totipotent stem cells are disclosed. Most preferably, such cells are obtained from various tissues of postnatal mammals (e.g., using tissue biopsied from the mammal), are smaller than 1 μm, have normal karyotype, and do not spontaneously differentiate in serum-free medium without differentiation inhibitors. These non-embryonic blastomere-like totipotent stem cells typically express CD66e, CEA-CAM-1 and telomerase, but do not typically express CD10, SSEA-1, SSEA-3, and SSEA-4. Such blastomere-like totipotent cells can be differentiated into ectodermal, mesodermal, or endodermal tissues, including placental tissues and germ cells. Moreover, when implanted into a mammal, such cells will not be teratogenic.

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng / ml of beta fibroblast growth factor (bFGF) are also described herein.

A novel human serrate-2 polypeptide consisting of a polypeptide containing the amino acid sequence described in SEQ ID NO: 1 in the Sequence Listing and having the effect of regulating the differentiation of undifferentiated cells involving stem cells; its gene; a process for producing the same; and an antibody specifically recognizing the polypeptide.

A medical device comprising a supporting structure having a coating on the surface thereof, the coating containing a therapeutic substance, such as, for example, a drug. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with a drug selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, cytostatic drugs, or combinations of these drugs.

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng / ml of beta fibroblast growth factor (bFGF) are also described herein.

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng / ml of beta fibroblast growth factor (bFGF) are also described herein.

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng / ml of beta fibroblast growth factor (bFGF) are also described herein.

A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to drugs of Formula (I). The drugs of Formula (I) can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, cytostatic drugs, or combinations of these drugs.

The invention relates to Id knockout mammals having a disruption in at least one and at most three alleles of inhibitor of differentiation genes, Id1 and Id3. This results in reduction or prevention of a cell proliferative disorder in the mammal as compared to a wild-type mammal. In particular, tumor growth and / or metastasis is shown to be inhibited. Further, tumor growth is shown to have poor vascularization and extensive necrosis in Id knockout mammals lacking 3 out of 4 of the Id1, Id3 alleles (Id1− / −Id3±). Drug screening methods to select agents useful to affect activity or expression of Id1 or Id3 gene products are disclosed. Therapeutic methods employing selected agents in subjects in need of treatment and diagnostic methods and test kits to identify subjects having, or at risk of having, a neurological or cell proliferative disorder are also described.

Provided are compositions and methods for inducing the self-renewal of stem / progenitor supporting cells, including inducing the stem / progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells, and including compositions and methods of using GSK3-alpha inhibitors, and salts thereof, optionally in combination with a Differentiation Inhibitor such as a Notch agonist or an HDAC inhibitor (e.g., valproic acid).

There are provided a protein which comprises the amino acid sequence of an extracellular region of Ror2 and is water-soluble, an osteoclast differentiation inhibitor for inhibiting differentiation of a precursor cell of osteoclast into an osteoclast, which comprises the protein as described above, an inflammatory bone resorption therapeutic agent for treating inflammatory bone resorption, which comprises the protein as described above, a gene which codes a protein comprising the amino acid sequence of an extracellular region of Ror2 and being water-soluble, a recombinant vector which comprises the gene as described above, a method of manufacturing a protein, which comprises a step of causing expression of a gene coding a protein comprising the amino acid sequence of an extracellular region of Ror2 and being water-soluble in a microorganism to synthesize the protein and a step of extracting the protein from the microorganism into water or an aqueous solution, a method of inhibiting osteoclast differentiation, which uses the protein as described above, and a method of treating inflammatory bone resorption, which uses a protein as described above.

The invention discloses a culture medium for rat embryonic stem cells. The culture medium comprises basal culture media and additives, wherein the additives comprise differentiation inhibitors and Pluripotin; and moreover, the differentiation inhibitors comprise GSK (Glycogen Synthase Kinase) inhibitors, FGFR (Fibroblast Growth Factor Receptor) inhibitors and MAPK (Mitogen-activated Protein Kinases) inhibitors. The invention also discloses a culture medium kit of the rat embryonic stem cells, a method for culturing the rat embryonic stem cells and applications of the culture medium and the kit, wherein the culture medium kit comprises the basal culture media, the differentiation inhibitors and the Pluripotin. With the adoption of the differentiation inhibitors and the Pluripotin, the culture medium for the rat embryonic stem cells can inhibit the differentiation of the rat embryonic stem cells and can further guarantee the stability of karyotype for reproductive potential.

The present invention belongs to genetic engineering and medical biotechnology field, providing a human differentiation inhibitor 3 expression vector, fusion protein and their preparing method. After PCR amplification, the expression vector makes hId3 gene clone between sites EcoR I and Sal I of fusion expression vector pET32a, recombinant expression vector hId3 / pET32a is produced. The invention makes hId3 encoding gene directly clone in prokaryotic expression vector, hId3 fusion protein expression vector is produced, realizing a high level expression of hId3 in escherichia coli, the expression accounts for 27% of bacterial protein, a whole set engineering bacteria induced expression and purification process are provided at the same time, rabbit anti-hId3 polyclonal antibody is produced by using hId3 fusion protein as an immunogen, laying a good foundation for researching biological function of hId3 protein and its application in clinical diagnose.

Provided is a method for constructing a chimeric embryo and a chimeric rat, characterized by comprising contacting rat pluripotent stem cells with a host embryo in the presence of an ES cell differentiation inhibitor. This method comprises a step (a) for contacting a host embryo, which is collected from a female rat after fertilization, with rat pluripotent stem cells in the presence of an ES cell differentiation inhibitor; and a step (b) for incubating the host embryo having been contacted with the rat pluripotent stem cells to form a chimeric embryo.

The present invention addresses the problem of providing an effective and highly safe osteoclast differentiation inhibitor and a food or beverage, a medicine, a supplement, and a cosmetic exhibiting an osteoclast differentiation-inhibiting effect. The problem is solved by an osteoclast differentiation inhibitor containing an urolithin.

The invention discloses an application of a substituted guanidyl-containing derivative in preparation of an osteoclast differentiation inhibitor. The substituted guanidyl-containing derivative has a direct and remarkable inhibition effect on RANKL-induced osteoclast differentiation and bone resorption activity, so that the substituted guanidyl-containing derivative can be used as an osteoclast differentiation inhibitor drug for treating diseases treated by an osteoclast differentiation inhibitor.

Provided is a method for suppressing an adipose differentiation comprising administering to a subject in need thereof a PPAR-v neddylation inhibitor for inhibiting adipocyte differentiation and a method for screening an adipocyte differentiation inhibitor using PPAR-v neddylation associated with adipocyte differentiation. The inhibitor of a neddylation pathway of PPAR-v inhibits the differentiation from mesenchymal stem cells to mast cells, and thus can be effectively used to treat obesity, and particularly, can be also useful in the treatment of severe obesity which cannot be excepted to be treated by existing obesity treatment agents.

The present invention relates to modified cells carrying a heterologous gene sequence encoding a protein, such as an Inhibitor of differentiation (Id) gene sequence that binds a basic helix-loop-helix (bHLH) protein to inhibit cell growth, differentiation and / or tumorigenesis of the modified cells. The modified cells are differentiated, proliferate and do not become tumorigenic when grafted into a recipient subject. Additionally, the modified cells produce a factor or factors that enhance the viability of co-grafted organs, tissues or cells. Thus, the modified cells are useful for testing agents for effects on the cells, for co-grafting with transplant organs, tissues or cells. The modified cells are also useful for enhancing the viability of thawing cells that have been cryo-preserved. In one embodiment, the modified cells are modified Sertoli cells.

The invention discloses a betulinic acid-amino acid derivative represented by a formula (I) and a preparation method thereof. The preparation method comprises the following steps of carrying out acylation reaction on a compound represented by a formula (a), acetic anhydride and pyridine under the protection of nitrogen so as to obtain a compound represented by a formula (b), reacting the compound of the formula (b) with oxalyl chloride so as to obtain a compound represented by a formula (c), then, respectively reacting the compound of the formula (c) with glycino methyl ester, L-alanine methyl ester, L-valine methyl ester, L-isoleucine methyl ester and L-glutamic acid methyl ester so as to obtain a compound represented by a formula (d), and washing, drying and purifying after reacting the compound of the formula (d) with LiOH so as to obtain the betulinic acid-amino acid derivative represented by the formula (I). The preparation method is high in synthetic efficiency and simple and convenient in process. The invention further discloses application of the betulinic acid-amino acid derivative represented by the formula (I) in preparation of a drug for treating osteoporosis; and the betulinic acid-amino acid derivative can be used as an osteoclast precursor differentiation inhibitor and has the obviously increased osteoclast precursor differentiation activity inhibition effect.

An object of the present invention is to provide an effective and highly safe agent for inhibiting osteoclast differentiation, and a food or drink, pharmaceutical, supplement, and cosmetic that produce an osteoclast differentiation-inhibiting effect; and the object is fulfilled by an agent for inhibiting osteoclast differentiation, comprising a urolithin.

The invention relates to application of erianin in preparation of an osteoclast differentiation inhibitor. Experiments prove that low-dose erianin can significantly inhibit RANKL and breast cancer induced mouse osteoclast generation and bone resorption activity; meanwhile, low-dose erianin can inhibit osteoclast precursor cells of a patient with breast cancer bone metastasis from generating polykaryotic osteoclasts, so that erianin can be used as an osteoclast differentiation inhibitor drug for treating diseases by an osteoclast differentiation inhibitor. The invention provides a new application of erianin, and also provides a new thought for treating bone destruction related diseases, tumor-induced bone destruction and other diseases.

The invention discloses application of a Flot2 inhibitor to inhibition of osteoclast formation and / or osteoclastic activity for the first time. The osteoclast generation and bone resorption induced byRANKL can be obviously reduced after the Flot2 expression is inhibited by Flot2-siRNA specific interference. A study team of the inventor discovers that the Flot2 directly participates in the osteoclast generation and bone resorption functions, and is possible to become a novel target of an osteoclast differentiation inhibitor. On the basis of the inhibition effect of Flot2-siRNA on osteoclasts and the application prospects of RNA interference medicine, the application of the Flot2 inhibitor as a medicine of inhibiting the osteoclast generation is provided.

A compound represented by formula (I); a process for producing a compound (substance F-1490) of formula (I), wherein X represents —O— and R represents a hydroxyl group, by using a microorganism belonging to the genus Cunninghamella; and a Cunninghamella sp. F-1490 strain (FERM BP-8287) capable of producing the substance F-1490; and an osteoclast differentiation inhibitory agent containing as an active ingredient the compound represented by formula (I):wherein X represents —O— or —CH2—, and R represents a hydroxyl group when X represents —O—, or a hydrogen atom when X represents —CH2—.